Characterization and Hsp104-induced artificial clearance of familial ALS-related SOD1 aggregates.
暂无分享,去创建一个
[1] J. Shorter,et al. Operational Plasticity Enables Hsp104 to Disaggregate Diverse Amyloid and Nonamyloid Clients , 2012, Cell.
[2] S. Tsuji,et al. A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis‐linked SOD1 mutants , 2012, Annals of neurology.
[3] A. Gitler,et al. Compartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity , 2012, Proceedings of the National Academy of Sciences.
[4] A. Biter,et al. Functional analysis of conserved cis- and trans-elements in the Hsp104 protein disaggregating machine. , 2012, Journal of structural biology.
[5] Sungsu Kim,et al. Ataxin-1 occupies the promoter region of E-cadherin in vivo and activates CtBP2-repressed promoter. , 2011, Biochimica et biophysica acta.
[6] M. Tuite,et al. Hsp70/Hsp90 co‐chaperones are required for efficient Hsp104‐mediated elimination of the yeast [PSI+] prion but not for prion propagation , 2009, Yeast.
[7] Seongman Kang,et al. Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: implications for the pathogenesis of amyotrophic lateral sclerosis , 2009, Experimental & Molecular Medicine.
[8] E. Foran,et al. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. , 2009, Antioxidants & redox signaling.
[9] F. Sanz,et al. Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils. , 2008, Journal of molecular biology.
[10] S. Lindquist,et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. , 2008, The Journal of clinical investigation.
[11] C. Behl,et al. Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation. , 2008, Human molecular genetics.
[12] K. Talbot,et al. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS , 2008, Progress in Neurobiology.
[13] Alberto Ferri,et al. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. , 2008, Antioxidants & redox signaling.
[14] Y. Shyu,et al. Visualization of AP-1–NF-κB ternary complexes in living cells by using a BiFC-based FRET , 2008, Proceedings of the National Academy of Sciences.
[15] J. Shorter. Hsp104: A Weapon to Combat Diverse Neurodegenerative Disorders , 2007, Neurosignals.
[16] V. Meininger,et al. Amyotrophic lateral sclerosis: all roads lead to Rome , 2007, Journal of neurochemistry.
[17] S. Walter,et al. Substrate Binding to the Molecular Chaperone Hsp104 and Its Regulation by Nucleotides* , 2005, Journal of Biological Chemistry.
[18] D. Rubinsztein,et al. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. , 2005, Human molecular genetics.
[19] R. Morimoto,et al. Structural properties and neuronal toxicity of amyotrophic lateral sclerosis–associated Cu/Zn superoxide dismutase 1 aggregates , 2005, The Journal of cell biology.
[20] L. Bruijn,et al. Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.
[21] M. Sowa,et al. The ClpB/Hsp104 molecular chaperone-a protein disaggregating machine. , 2004, Journal of structural biology.
[22] Mark A Rizzo,et al. An improved cyan fluorescent protein variant useful for FRET , 2004, Nature Biotechnology.
[23] Jimena Weibezahn,et al. Characterization of a Trap Mutant of the AAA+ Chaperone ClpB* , 2003, Journal of Biological Chemistry.
[24] Takeharu Nagai,et al. Shift anticipated in DNA microarray market , 2002, Nature Biotechnology.
[25] M. Tuite,et al. The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation , 2001, Molecular microbiology.
[26] J. Shefner,et al. Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy , 1999, Neurology.
[27] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.